Dedicated Bifurcation Cobalt-Chromium Sirolimus-Eluting Stent in the Treatment of Distal Left Main Stenosis: Optical Coherence Tomography Evaluation of the Stent Healing Pattern - European Medical Journal

Dedicated Bifurcation Cobalt-Chromium Sirolimus-Eluting Stent in the Treatment of Distal Left Main Stenosis: Optical Coherence Tomography Evaluation of the Stent Healing Pattern

2 Mins
Interventional Cardiology
*Jacek Bil,1 Robert J. Gil,1 Adam Kern,2 Tomasz Pawlowski1

Dr Gil has served as a medical consultant for the Balton Company. The remaining authors have declared no conflicts of interest.

EMJ Int Cardiol. ;6[1]:56-57. Abstract Review No. AR10.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


The optimal form of treatment for left main (LM) coronary artery disease, a form of atherosclerosis, is still debated. The aim of this study was to assess the effectiveness and safety profile of the distal LM stenosis treatment with the new cobalt-chromium sirolimus-eluting BiOSS LIM® C stent (Bifurcation Optimization Stent System, Warsaw, Poland).1-3


BiOSS LIM C is a coronary-dedicated bifurcation sirolimus-eluting balloon expandable stent made of cobalt-chromium (strut thickness: 70 µm). It is coated with a biodegradable polymer comprised of lactic and glycolic acids. The polymer releases sirolimus in a time-controlled manner lasting around 8 weeks. The stent consists of two parts with different diameters connected with two struts 1.7 mm in length. BiOSS LIM C is mounted on a dedicated bifurcation balloon, Bottle® (Balton, Warsaw, Poland). The stent delivery is a rapid exchange system.4-7 Between September 2016 and December 2017, patients from two Polish centres with a final diagnosis of stable coronary artery disease or acute coronary syndrome without ST-segment elevation who had signed informed consent documents were enrolled. Patients with ST-elevation myocardial infarction (MI) or Medina type 001 bifurcation lesions were excluded from the registry. Provisional T-stenting was the obligatory strategy. Double antiplatelet therapy is planned for 6–12 months. An angiographic control with intravascular ultrasound or optical coherence tomography (OCT) is planned at 12 months. The primary endpoint is the rate of cardiac death, MI, and target lesion revascularisation at 12 months. The authors have presented the interim results here.


The study so far included 53 patients with stable coronary artery disease or non-ST-elevation acute coronary syndrome (67.9% versus 32.1%, respectively). The mean age of enrolled patients (77.4% males) was 66.26±8.57 years. There were 47 (88.7%) patients with hypertension, 23 (43.4%) with diabetes, and 30 (56.6%) with prior MI. Additionally, 28 patients (52.8%) underwent prior percutaneous coronary intervention, while 11 (20.8%) patients had previous coronary artery bypass graft. The mean SYNTAX score was 22.52±7.58 and EuroScore II was 1.62%±1.70%. True bifurcations were treated in 70.1% of cases. According to the Medina classification, true bifurcations were present in 70.0% of cases. All BiOSS stents were implanted successfully (average pressure: 15 atm). The mean nominal stent parameters were as follows: 4.17±0.36 mm x 3.42±0.35 mm x 19.94±3.16 mm. In 15 (28.3%) cases, the second stent was implanted within the side branch with the use of the T and protrusion technique. The proximal optimisation technique was performed in 37 cases (69.8%), and in 92.5% this required radial access. In 3 cases (5.7%) periprocedural MI was diagnosed. At 1 (n=51) and 3 (n=47) months, all patients had not experienced any cardiac event (out-of-hospital major adverse cardiac event rate was 0%). At 12 months (half of the patients were controlled) in OCT analysis neointima burden was comparable between proximal and distal part of the stent and did not exceed 30%.


New dedicated bifurcation BiOSS LIM C stents seem feasible devices with promising effectiveness and safety in distal LM stenosis. Complete BiOSS LIM C angiographic and OCT data will answer the question as to whether the new stent platform with thin struts that was used is advantageous.

Gil RJ et al. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - Three-month results. Kardiol Pol. 2018;76(2):464-70. Bil J et al. Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model. Cardiovasc Ther. 2017;35(4). Gil RJ et al. BiOSS LIM C: Thin-strut cobalt-chromium version of the dedicated bifurcation stent. Expert Rev Med Devices. 2017;14(4):279-84. Bil J et al. Self-positioning properties of dedicated bifurcation coronary stent BiOSS LIM® in the eye of 3D optical coherence tomography. Minerva Cardioangiol. 2017;65(2):194-6. Gil RJ et al. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies. Cardiol J. 2017. [Epub ahead of print]. Gil RJ et al. Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS® stents for coronary bifurcation treatment: Four-year results of randomized POLBOS I and POLBOS II clinical trials. EuroIntervention. 2018. pii: EIJ-D-18-00172. [Epub ahead of print]. Gil RJ et al. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up. Int J Cardiovasc Imaging. 2018;34(3):353-65.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now